Adjuvant dose-dense chemotherapy in breast cancer: a systematic review and meta-analysis of randomized trials | SpringerLink
Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2) - ScienceDirect
Table 3 from Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks.
Trial design of AGO trial, intense dose-dense epirubicin, paclitaxel,... | Download Scientific Diagram
Impact of dose-dense neoadjuvant chemotherapy on pathologic response and survival for HER2-positive breast cancer patients who receive trastuzumab | npj Breast Cancer
Dose-dense adjuvant chemotherapy for primary breast cancer | Breast Cancer Research | Full Text
Dose-dense chemotherapy for breast cancer: what does the future hold? | Future Oncology
Impact of dose-dense neoadjuvant chemotherapy on pathologic response and survival for HER2-positive breast cancer patients who receive trastuzumab | npj Breast Cancer
Current status of dose-dense chemotherapy for breast cancer | SpringerLink
Optimising dose-dense regimens for early breast cancer | Cancer World Archive
Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studi
Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial - ScienceDirect
Optimising dose-dense regimens for early breast cancer | Cancer World Archive
PDF) P123 Preoperative sequential chemotherapy of dose-dense epirubicin/cyclophosphamide followed by docetaxel/capecitabine in patients with stage II/IIIA breast cancer | C. Natoli - Academia.edu
Frontiers | PELICAN-IPC 2015-016/Oncodistinct-003: A Prospective, Multicenter, Open-Label, Randomized, Non-Comparative, Phase II Study of Pembrolizumab in Combination With Neo Adjuvant EC-Paclitaxel Regimen in HER2-Negative Inflammatory Breast Cancer
Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial - The Lancet
Standard vs dose-dense adjuvant chemotherapy in hormone... | Download Scientific Diagram
Optimising dose-dense regimens for early breast cancer | Cancer World Archive
Optimising dose-dense regimens for early breast cancer | Cancer World Archive
Survival outcomes for dose‐dense paclitaxel plus carboplatin neoadjuvant vs standard adjuvant chemotherapy in stage II to III triple‐negative breast cancer: A prospective cohort study with propensity‐matched analysis - Xiu - 2022 -
Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. | Semantic Scholar
4102-Breast adjuvant/neoadjuvant AC (DOXOrubicin and CYCLOPHOSPHamide) dose dense | eviQ
Systemic chemotherapy of breast cancer: adjuvant and neoadjuvant Systemic chemotherapy of breast cancer: adjuvant and neoadjuvant Alexandru Eniu, MD, PhD. - ppt download
